查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1717175

多囊性腎病藥物市場（按藥物類型、給藥方式、疾病類型、通路和最終用戶分類）－2025-2030 年全球預測

Polycystic Kidney Disease Drugs Market by Drug Type, Mode of Administration, Disease Type, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

多囊性腎病藥物市場預計到 2024 年將達到 5.3954 億美元，2025 年將達到 5.6392 億美元，到 2030 年將達到 7.0801 億美元，複合年成長率為 4.63%。

執行摘要簡介：為全面了解多囊性腎病變藥物奠定基礎

主要市場統計數據
基準年2024年 5.3954億美元
預計2025年 5.6392億美元
預測年份 2030 7.0801億美元
複合年成長率（%） 4.63%

多囊性腎病變 (PKD) 帶來了複雜的臨床挑戰，需要持續創新並深入了解市場。該報告首先對當前情況進行了廣泛的調查，旨在為需要臨床和商業洞察力的相關人員提供清晰、有根據的介紹。 PKD 治療的不斷發展，加上藥物開發的最新突破，凸顯了該領域正在經歷轉型期。在這裡，我們重點介紹不斷發展的治療方案、臨床研究的最新趨勢以及影響治療策略的醫療保健模式的變化。

我們的分析深入研究了過去的市場趨勢，並將其與新數據相結合，以幫助專業人士更好地預測和引領 PKD 治療市場的未來。由於治療效果和病人安全仍然是這項變革的重中之重，因此介紹將深入探討變革性的市場變化、關鍵細分細微差別和區域績效促進因素。本報告將為尋求最佳化治療策略和發現這個獨特市場的成長機會的決策者提供重要資源。

本介紹旨在吸引臨床專家、醫藥負責人、策略規劃人員和其他人的注意。準確、全面地了解 PKD 藥物治療的現狀，為理解臨床創新滿足市場需求的複雜生態系統提供了基礎。

PKD藥物格局正在改變：應對治療和市場動態的新現實

近年來，PKD 治療環境一直在變革時期，反映了臨床和法規環境的變化。醫學研究的進步和新型藥物的引入逐漸重新定義了這種多方面疾病的治療方法。傳統的治療方法已經被更有針對性的治療方法所取代，這些治療方法旨在減輕潛在疾病的進展，而不僅僅是控制症狀。治療模式的演變是由嚴格的臨床試驗和對 PKD 分子機制的深入了解所推動的。

市場領導者發現的重大轉變之一是轉向個人化治療方法。隨著臨床試驗數據的積累，針對特定患者的治療方案的轉變變得越來越明顯。這項運動進一步推動了數位健康技術的整合，簡化了患者監測和治療方案的遵守。創新配方的出現也有助於提高療效並減少副作用的發生，進而改善患者的整體治療效果。

同時，監管機構透過制定促進創新並確保患者安全的框架來適應這些快速發展。這種平衡的方法促進了有前景的藥物的快速核准流程，縮短了先進治療方案的上市時間。此外，產業和監管機構的積極參與為臨床研究人員和製藥商共同努力解決未滿足的臨床需求的更具協作性的環境鋪平了道路。

從策略上講，製藥公司正在重新調整投資計劃，重點是精準醫療和數位整合等具有高潛在回報的關鍵領域。這種重新平衡不僅刺激了市場領導者之間的競爭，而且擴大了可用治療選擇的範圍。因此，患者護理變得更加個人化和響應性，開創了多囊性腎病管理的新時代。

關鍵細分洞察揭示藥品類型、給藥方式、疾病類型、分銷管道和最終用戶的複雜性

徹底的細分分析揭示了多層次的市場結構，這對於制定有針對性的治療策略至關重要。就藥物類型而言，產品組合多樣化，其中血管收縮素II 受體拮抗劑、血管收縮素轉化酵素抑制劑和鈣通道阻斷劑發揮核心作用，同時還有 mTOR 抑制劑、生長抑制素類似物和加壓素受體拮抗劑等創新類別。競爭頻譜凸顯了了解每種藥物的獨特作用機制和患者適用性的重要性。公司正在加大改良配方的投資，不僅為了提高療效，也為了最佳化病人的依從性。

要考慮的另一個方面是管理方法。分析發現，雖然靜脈注射和注射給藥因其起效迅速而在臨床實踐中越來越受歡迎，但口服給藥因其便利性和患者偏好仍然佔據主導地位。這種雙重動態要求相關人員在注射療法的即時有效性與口服療法的更廣泛、更長期的依從性益處之間取得平衡。這些管理上的差異通常決定臨床試驗的結構並指導新藥物傳輸系統的發展。

疾病類型進一步使市場複雜化，分為常染色體顯性多囊性腎病變和常染色體隱性多囊性腎病變。這種分類非常重要，因為它不僅影響患者的人口統計，也影響所需的治療方法。體染色體顯性遺傳病例佔患者的大多數，需要長期管理方案以減緩病情進展，而體染色體隱性遺傳病例則需要更快速、更密集的干涉。

細分分析也延伸至銷售管道。該市場由包括醫院藥房、網路藥房和零售藥房在內的複雜網路支撐。醫院藥房在急性護理中發揮關鍵作用，而線上和零售藥房則為門診護理提供了更廣泛的管道。這種多通路分銷策略旨在最佳化覆蓋範圍並確保患者無論身在何處都能及時獲得尖端治療方法。

最後，以診所、家庭護理機構和醫院為重點的最終用戶細分揭示了支持 PKD 患者所需的護理水平和資源分配的差異。診所和醫院可以提供由專家主導的即時干預，而家庭護理環境越來越受到遠端監控技術和專業藥物護理的支持。這些部分相互交織，凸顯了市場的複雜性，並促使採取多方面的銷售和分銷策略來滿足每個最終用戶場景的特定需求。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 多囊性腎病的盛行率在世界各地不斷上升，推動了對創新治療方法的需求。
      • 加強政府政策和獎勵的實施，促進治療方法的發展
      • 加強病患教育和宣傳宣傳活動，鼓勵病患採取積極主動的疾病管理方法
    • 限制因素
      • 對產品召回和不利事件的擔憂
    • 機會
      • 利用 mTOR 抑制劑和加壓素受體拮抗劑的進展擴大藥物研發管線
      • 擴大夥伴關係關係和合作潛力，開發有效藥物
    • 任務
      • 克服新型多囊性腎病變治療的監管障礙和複雜的核准流程
  • 市場區隔分析
    • 藥物類型：mTOR抑制劑在針對細胞增生路徑治療的巨大優勢
    • 最終用戶：多囊性腎病藥物在高發生率都市區診所的應用快速成長
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 多囊性腎病藥物市場（依藥物類型）

  • 血管收縮素II 受體阻斷劑
  • 血管張力素轉化酵素抑制劑
  • 鈣離子通道阻斷劑
  • mTOR抑制劑
  • 生長抑制素類似物
  • 加壓素受體拮抗劑

7. 多囊性腎病藥物市場（依給藥方式）

  • 靜脈注射（IV）或注射
  • 口服

8. 多囊性腎病藥物市場（依疾病類型）

  • 常染色體顯性多囊性腎病變
  • 常染色體隱性多囊性腎病變

9. 多囊性腎病藥物市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 10 章多囊性腎病藥物市場（依最終用戶）

  • 診所
  • 居家照護環境
  • 醫院

11. 美洲多囊性腎病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太多囊腎病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲多囊性腎病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Apotex Inc.
  • Boehringer Ingelheim GmbH
  • Centessa Pharmaceuticals Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Galapagos NV
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-62667ADF9FE1

The Polycystic Kidney Disease Drugs Market was valued at USD 539.54 million in 2024 and is projected to grow to USD 563.92 million in 2025, with a CAGR of 4.63%, reaching USD 708.01 million by 2030.

Executive Summary Introduction: Laying the Groundwork for Comprehensive Insights on Polycystic Kidney Disease Drugs

KEY MARKET STATISTICS
Base Year [2024] USD 539.54 million
Estimated Year [2025] USD 563.92 million
Forecast Year [2030] USD 708.01 million
CAGR (%) 4.63%

Polycystic Kidney Disease (PKD) presents a complex clinical challenge that requires continuous innovation and detailed market understanding. This report commences with an extensive exploration of the current landscape, aiming to offer a clear, well-grounded introduction for stakeholders who demand insight into both clinical and commercial avenues. The evolving dynamics of PKD treatment, coupled with the latest breakthroughs in drug development, underscore a sector in transition. Here, we illuminate the evolution of treatment options, recent developments in clinical research, and the shifting paradigms in healthcare delivery that are influencing treatment strategies.

Our analysis delves into historical market trends and aligns them with emerging data, enabling professionals to better forecast and navigate the future of PKD drug markets. As therapeutic efficacy and patient safety remain at the forefront of this evolution, the introduction sets the stage for a meticulous exploration of transformative market shifts, key segmentation nuances, and regional performance factors. In doing so, the report provides an indispensable resource for decision-makers intent on optimizing treatment strategies and identifying growth opportunities within this specialized market.

This introduction is designed to quickly capture the attention of clinical experts, pharmaceutical marketers, and strategic planners alike. By offering an accurate and comprehensive snapshot of the current state of PKD drug therapies, the ensuing discussions create a foundation for understanding the complex ecosystem where clinical innovation meets market demand.

Transformative Shifts in the PKD Drug Landscape: Navigating New Realities in Treatment and Market Dynamics

In recent years, the PKD drug landscape has undergone transformative shifts that reflect broader changes in both clinical practices and regulatory environments. Advancements in medical research and the introduction of novel pharmacological agents have gradually redefined the approach to treating this multifaceted condition. Traditional therapeutic methodologies have been supplanted by more targeted treatments that not only emphasize the management of symptoms but also aim to mitigate the underlying disease progression. This evolution in treatment paradigms has been driven by robust clinical trials and an increasing understanding of the molecular mechanisms underpinning PKD.

One of the major shifts identified by market leaders is the transition towards therapies that incorporate personalized medicine. As clinical trial data accumulates, a shift toward patient-specific regimens is becoming increasingly apparent. This movement is further supported by the integration of digital health technologies, which are streamlining patient monitoring and adherence to treatment protocols. The emergence of innovative drug formulations has also contributed to better efficacy and lower incidence of adverse side effects, thereby enhancing overall patient outcomes.

Concurrently, regulatory bodies have adapted to these rapid evolutions by developing frameworks that encourage innovation while ensuring patient safety. This balanced approach has facilitated quicker approval processes for promising drugs, thus reducing the time-to-market for advanced therapeutic options. Moreover, the proactive engagement between industry and regulatory authorities has paved the way for a more collaborative environment, in which clinical researchers and pharmaceutical manufacturers work together to address unmet clinical needs.

Strategically, pharmaceutical companies are recalibrating their investment plans to concentrate on key areas that promise high returns, such as precision therapies and digital integration. This recalibration has not only spurred heightened competition among major market players but also expanded the range of available treatment options. As a result, patient care is becoming more individualized and responsive, marking a new era in the management of polycystic kidney disease.

Key Segmentation Insights: Uncovering Intricacies Across Drug Type, Mode of Administration, Disease Type, Distribution Channel, and End-User

Our in-depth segmentation analysis reveals a multilayered market structure that is essential for crafting targeted treatment strategies. Insights into the drug type indicate a well-diversified portfolio, where formulations such as Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, and Calcium Channel Blockers take center stage alongside innovative categories like mTOR Inhibitors, Somatostatin Analogs, and Vasopressin Receptor Antagonists. The competitive spectrum underscores the importance of understanding the unique mechanisms of action and patient suitability for each drug class. Companies are increasingly investing in enhanced formulations that not only improve efficacy but also optimize patient adherence.

Another dimension that merits attention is the mode of administration. Analysis shows that while intravenous or injectable options are gaining traction in clinical settings due to their rapid onset of action, oral administration continues to dominate given its convenience and patient preference. This dual dynamic requires stakeholders to balance the immediate impact of injectable therapies with the broader, long-term compliance benefits of oral regimens. The distinctions between these modes often dictate the structuring of clinical trials and direct the development of new drug delivery systems.

Disease type further complicates the market landscape, where a bifurcation is observed between Autosomal Dominant Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease. This classification is critical as it not only affects the patient demographic but also influences the therapeutic modality required. Autosomal Dominant cases, which represent a significant share of the patient pool, necessitate long-term management solutions aimed at slowing disease progression, while Autosomal Recessive instances call for more immediate, intensive intervention.

The segmentation analysis extends into the distribution channel. The market is supported by an intricate network involving hospital pharmacies, online pharmacies, and retail pharmacies. Each channel has its distinct set of drivers, with hospital pharmacies playing a crucial role in acute care settings, and online or retail channels providing wide accessibility to outpatient treatments. This multi-channel distribution strategy is crafted to optimize reach and ensure that patients have timely access to cutting-edge therapies wherever they are located.

Lastly, the end-user segmentation that focuses on clinics, homecare settings, and hospitals reveals insights into the differing levels of care and resource allocation necessary to support PKD patients. Clinics and hospitals can facilitate immediate, expert-driven interventions, while homecare settings are increasingly being supported by remote monitoring technologies and specialized pharmaceutical care. The intertwined nature of these segments underscores the complexity of the market, driving a multi-pronged approach to sales and distribution strategies that cater to the specific needs of each end-user scenario.

Based on Drug Type, market is studied across Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, mTOR Inhibitors, Somatostatin Analogs, and Vasopressin Receptor Antagonists.

Based on Mode of Administration, market is studied across Intravenous (IV) or Injectable and Oral.

Based on Disease Type, market is studied across Autosomal Dominant Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.

Key Regional Insights: Analyzing Market Dynamics Across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional analysis of the PKD market highlights significant variations in market dynamics, regulatory environments, and healthcare infrastructure. In the Americas, the market is bolstered by robust healthcare funding, advanced clinical infrastructure, and a strong focus on research and development. This region is characterized by a proactive adoption of innovative treatment methodologies and a comprehensive healthcare system that supports both acute and chronic care models.

In the Europe, Middle East & Africa region, a diverse mix of emerging markets and established healthcare systems creates a dynamic environment where progressive regulatory reforms align with growing investments in healthcare. The region is notable for its balanced approach to cost control and the adoption of advanced therapeutic options. Driven by heightened public awareness and governmental support, this region is steadily gaining ground in terms of market penetration and clinical outcomes.

In the Asia-Pacific region, rapid economic growth coupled with an expanding middle class has led to increased healthcare investments. The region is witnessing an accelerated adoption of novel therapeutic solutions, propelled by advancements in pharmaceutical manufacturing and burgeoning research and development initiatives. This growth is further accelerated by government policies that encourage innovation in drug discovery and a strong focus on patient-centric care models. The contrasting healthcare environments across these regions underscore the need for tailored strategies that respect local nuances while leveraging global best practices.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights: Market Leaders Shaping the Future of PKD Therapeutics Through Strategic Vision and Innovation

A review of key companies in the PKD drug market reveals how strategic vision and innovative approaches are catalyzing the development of next-generation therapies. Market leaders such as Apotex Inc. and Boehringer Ingelheim GmbH have long been at the forefront of drug development, harnessing advanced research platforms to push the boundaries of traditional treatment approaches. Centessa Pharmaceuticals Limited and Eli Lilly and Company are leveraging deep clinical expertise to refine patient-focused therapies, while F. Hoffmann-La Roche AG and Fresenius Kabi AG continue to invest heavily in improving drug safety profiles and enhancing the therapeutic index of existing compounds.

Innovation is equally palpable among emerging players like Galapagos NV and Kyowa Hakko Kirin Co., Ltd., whose research into novel mechanisms of action is opening up new therapeutic pathways. Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation have robust portfolios that reflect years of clinical experience and a commitment to patient-centric care, further reinforced by the strategic investments made by Novartis International AG and Otsuka Pharmaceutical Co., Ltd. These organizations not only emphasize product efficacy but also prioritize integrated healthcare solutions that encompass patient support services.

The competitive landscape is rounded out by cutting-edge companies such as Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, and Viatris Inc., all of which are making significant contributions to the field of PKD therapeutics. Their work is characterized by rigorous clinical studies, an emphasis on precision medicine, and the development of digital health tools that enhance patient engagement. Collectively, these companies are driving a landscape where innovation and market responsiveness are interwoven, ensuring that therapeutic advancements are delivered effectively to meet diverse patient needs.

The report delves into recent significant developments in the Polycystic Kidney Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Boehringer Ingelheim GmbH, Centessa Pharmaceuticals Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Fresenius Kabi AG, Galapagos NV, Kyowa Hakko Kirin Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, and Viatris Inc.. Actionable Recommendations: Strategic Considerations to Propel Market Growth and Strengthen Competitive Advantage in PKD Drugs

Industry leaders are encouraged to adopt a multi-dimensional strategy that aligns clinical innovation with market dynamics. First and foremost, there is a pressing need to maintain a patient-centric focus. Investment in personalized medicine should be prioritized to tailor therapies based on the specific genetic and clinical profiles of PKD patients. Embracing digital health solutions that facilitate remote patient monitoring and data-driven decision-making can further enhance this personalization.

Simultaneously, companies should consider diversifying their drug portfolios by advancing research in both traditional therapies and novel treatments. Integrating clinical trials that combine innovative therapeutic modalities with environmental and genetic data will help in carving out competitive niches. It is also advisable to develop strategic alliances with academic institutions, technology firms, and regional healthcare providers. This collaborative approach not only enriches research capabilities but also speeds up the transition of promising drug candidates from laboratory settings to commercial viability.

Furthermore, optimizing distribution channel strategies is critical. Firms must adopt robust, multi-modal distribution frameworks that ensure swift access to therapies across hospital pharmacies, online platforms, and retail outlets. This requires a balanced logistical structure that supports both centralized and decentralized distribution modes. Additionally, fostering relationships with healthcare providers operating in clinics, homecare settings, and hospitals can help in streamlining the delivery of new treatments, thereby enhancing market penetration.

Regulatory agility is another cornerstone of a proactive business strategy. Companies should develop dedicated regulatory teams that are equipped to navigate the evolving global landscape. By engaging in consistent dialogue with regulatory bodies and adopting best practices from regions with progressive guidelines, organizations can mitigate potential delays in drug approval processes, ultimately contracting the time-to-market for innovative therapies.

Lastly, leveraging market analytics and segmentation insights is vital for tailoring product development and marketing strategies. Understanding the nuanced differences across drug types, modes of administration, and disease classifications enables companies to better position their offerings. An analytical approach that integrates real-world data and consumer feedback will allow for the customization of strategic actions and drive sustainable growth in a competitive market environment.

Conclusion: Synthesizing Critical Insights and Implications for the Future of PKD Drug Therapies

In summary, the evolving landscape of polycystic kidney disease drugs is defined by rapid advancements in clinical research, strategic market realignments, and an ongoing shift toward patient-centric care. This comprehensive analysis highlights the importance of a multifaceted approach that integrates clinical breakthroughs with strategic segmentation. The detailed examination of drug type, mode of administration, disease category, distribution channel, and end-user perspectives reveals critical performance benchmarks and growth opportunities that are reshaping the market.

Moreover, regional insights indicate that while the Americas and Europe, Middle East & Africa continue to lead with established healthcare systems and research infrastructures, the Asia-Pacific region emerges as a dynamic hotspot with significant growth potential. Meanwhile, leading companies are setting the pace for innovative therapeutics by harnessing robust R&D frameworks, deep clinical expertise, and agile regulatory strategies.

The synthesis of these insights underscores a clear imperative for industry stakeholders: to continuously realign their strategies in response to emerging trends, to invest in groundbreaking research, and to enhance patient support mechanisms across all channels. The future trajectory of PKD drug therapies is set to benefit from this integrated approach, paving the way for more effective, targeted treatments that address the pressing clinical needs of a diverse patient population.

This conclusion serves as a call for sustained innovation and strategic foresight as the market continues to evolve. It emphasizes that success in this arena will depend on the ability to adapt to changing clinical paradigms while maintaining a relentless focus on patient outcomes and technological integration.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of polycystic kidney disease worldwide is fueling need for innovative treatments
      • 5.1.1.2. Growing implentation of government policies and incentives for the development of treatments
      • 5.1.1.3. Increasing patient education and awareness campaigns encouraging proactive approaches to disease management
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with product recall and adverse findings of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of the drug pipeline with advancements for mTOR inhibitors and vasopressin receptor antagonists
      • 5.1.3.2. Growing potential with partnerships and collaborations for the development of effective drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating regulatory hurdles and complex approval processes for new polycystic kidney disease drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Significant benefits of mTOR inhibitors for targeting cellular growth pathways in treatment
    • 5.2.2. End-User: Proliferating applications of polycystic kidney disease drugs in clinics for high disease prevalence in urban settings
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Polycystic Kidney Disease Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Angiotensin II Receptor Blockers
  • 6.3. Angiotensin-Converting Enzyme Inhibitors
  • 6.4. Calcium Channel Blockers
  • 6.5. mTOR Inhibitors
  • 6.6. Somatostatin Analogs
  • 6.7. Vasopressin Receptor Antagonists

7. Polycystic Kidney Disease Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Intravenous (IV) or Injectable
  • 7.3. Oral

8. Polycystic Kidney Disease Drugs Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Autosomal Dominant Polycystic Kidney Disease
  • 8.3. Autosomal Recessive Polycystic Kidney Disease

9. Polycystic Kidney Disease Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Polycystic Kidney Disease Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare Settings
  • 10.4. Hospitals

11. Americas Polycystic Kidney Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Polycystic Kidney Disease Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Polycystic Kidney Disease Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Regulus Therapeutics announces promising ADPKD results and FDA alignment for Farabursen
    • 14.3.2. Mitsui Chemicals invests in Rege Nephro to advance kidney disease therapies
    • 14.3.3. Maze Therapeutics launches phase 1 Trial for novel CKD treatment MZE782
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Boehringer Ingelheim GmbH
  • 3. Centessa Pharmaceuticals Limited
  • 4. Eli Lilly and Company
  • 5. F. Hoffmann-La Roche AG
  • 6. Fresenius Kabi AG
  • 7. Galapagos NV
  • 8. Kyowa Hakko Kirin Co., Ltd.
  • 9. Merck & Co., Inc.
  • 10. Mitsubishi Tanabe Pharma Corporation
  • 11. Novartis International AG
  • 12. Otsuka Pharmaceutical Co., Ltd.
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Vertex Pharmaceuticals Incorporated
  • 17. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 238. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024